Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

RALOXIFENE HCL

All products: Limited Use (codes 373)

Other products in the same Health Canada class (G03X) — coverage varies; not interchangeable

  • Mifepristone + misoprostol (Mifegymiso): not a benefit

Evista · DIN 02239028 · 60mg · tablet

Limited Use — Reason for Use code 373 required; Health Canada lists this DIN as Cancelled post market since 2026-01-30 — choose a marketed DIN from the same-category list.Discontinued 2026-01-30 · checked 2026-09-19
StatusLimited Use — Reason for Use code 373 required; Health Canada lists this DIN as Cancelled post market since 2026-01-30 — choose a marketed DIN from the same-category list.
Write on scriptLU code 373 (patient must meet the criteria below); Health Canada lists this DIN as Cancelled post market since 2026-01-30 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 373
Coverage limit: For the treatment of osteoporosis in postmenopausal women who have: Reason for Use code 373 Failed or, experienced intractable side effects, or have a contraindication to, alendronate OR risedronate. Coverage limit: Failure is defined as: continued loss of bone mineral density (loss of more than 3%) after two years of therapy; or a new osteoporosis related fracture after one year of therapy. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Evista · DIN 02239028 Manufacturer: Eli Lilly Canada Inc.; listing date 2000-11-30 Health Canada: Cancelled post market since 2026-01-30 · brand EVISTA · ATC G03XC01 RALOXIFENE · form Tablet · route Oral · ingredients RALOXIFENE HYDROCHLORIDE 60 MG · company Eli lilly canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.5134 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62480 · Verify on the e-Formulary ↗ (DIN 02239028)

Source record
DIN 02239028: Evista Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000323; group id 950; item number 2256; lccId 00133; manufacturer id LIL Source form: Tab; strength: 60mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $2.3757; ministry $0.5134 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239028 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62480
Interchangeable products
Act Raloxifene · DIN 02358840 · $0.5134 Apo-Raloxifene · DIN 02279215 · $0.5134 Jamp Raloxifene · DIN 02540681 · $0.5134
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2026-01-30 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

MIFEPRISTONE & MISOPROSTOL

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 200mg & 200mcg · Tab Kit Pk

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: osteoporosis in postmenopausal women
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL ALENDRONATE & CHOLECALCIFEROL · General benefit 1 INDICATIONS FOSAVANCE® (alendronate sodium/cholecalciferol) is indicated for: • The treatment of osteoporosis in postmenopausal women. PM: https://pdf.hres.ca/dpd_pm/00071923.PDF; date not captured; DIN 02276429; fetched 2026-09-10 Product monograph RISEDRONATE SODIUM · General benefit (20), Listed, not a benefit (3) For the prevention of osteoporosis in postmenopausal women who are at risk of developing osteoporosis, ACTONEL preserves or increases BMD at sites of clinical importance. PM: https://pdf.hres.ca/dpd_pm/00068139.PDF; date NOV 3, 2022; DIN 02246896; fetched 2026-09-10 Product monograph  The treatment of osteoporosis in postmenopausal women PM: https://pdf.hres.ca/dpd_pm/00068139.PDF; date NOV 3, 2022; DIN 02246896; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE APO-RALOXIFENE (raloxifene hydrochloride) is indicated for the treatment and prevention of osteoporosis in postmenopausal women. For either osteoporosis treatment or prevention, supplemental calcium and/or vitamin D should be added to the diet if daily intake is inadequate. Postmenopausal osteoporosis may be diagnosed by history or radiographic documentation of osteoporotic fracture, bone mineral densitometry, or physical signs of vertebral crush fractures (e.g., height loss, dorsal kyphosis). Women with diagnosed postmenopausal osteoporosis should be considered for pharmacologic therapy, in conjunction with education and appropriate lifestyle modifications. No single clinical finding or test result can quantify risk of postmenopausal osteoporosis with certainty. However, clinical assessment can help to identify women at increased risk. Widely accepted risk factors include Caucasian or Asian descent, slender body build, early estrogen deficiency, smoking, alcohol consumption, low calcium diet, sedentary lifestyle, personal history of any fracture after age 40 and family history of osteoporosis. Evidence of increased bone turnover from serum and urine… https://pdf.hres.ca/dpd_pm/00002184.PDF PM date: not printed or not captured Source product: APO-RALOXIFENE; DIN 02279215; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.